CompletedNot Applicable

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

21,692 participantsStarted 2009-01-01

Plain-language summary

The goal of this observational study is to learn if a specific diabetes medicine can lower the risk of lung cancer in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: \- Does taking medicines called SGLT2 inhibitors lower the chance of getting lung cancer compared to medicines called sulfonylureas? Researchers will compare the medical records of people taking SGLT2 inhibitors to those taking sulfonylureas to see if the SGLT2 group has fewer cases of lung cancer. Participants will not need to visit a doctor or take new medicines for this study. Researchers will use information from existing medical records to answer the research question.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged ≥40 years with prior COPD (from 2009) and newly diagnosed diabetes who initiated SU or SGLT2i between January 1, 2014 and December 31, 2023 Exclusion Criteria: * Pre-existing * ESRD * Cancer * Concurrent prescribing of the study drugs at the index date * Exposure to the drugs of interest during the year preceding the index date * Death or cancer incidence within a month In the sensitivity analysis, we are planning to substitute sulfonylurea to DPP4 inhibitors.

What they're measuring

Lung cancer

Timeframe: From index date + 30 days to the end of follow-up

Trial details

NCT IDNCT07332156

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Type 2 Diabetes trials